دورية أكاديمية
أعرض في EDS

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

التفاصيل البيبلوغرافية
العنوان: Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
المؤلفون: Jingjing Lv, Hui Wu, Junjie Xu, Jiaye Liu
المصدر: Infectious Diseases of Poverty, Vol 11, Iss 1, Pp 1-17 (2022)
بيانات النشر: BMC, 2022.
سنة النشر: 2022
المجموعة: LCC:Infectious and parasitic diseases
LCC:Public aspects of medicine
مصطلحات موضوعية: Homologous vaccination, Heterologous vaccination, COVID-19, Immunogenicity, Safety, Infectious and parasitic diseases, RC109-216, Public aspects of medicine, RA1-1270
الوصف: Abstract Background Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation. This review aimed to synthesize immunogenicity and reactogenicity of heterologous immunisations with ChAd and BNT (mRNA-1273) vaccine compared with homologous ChAd or BNT (mRNA-1273) immunisation. Methods PubMed, Web of Science, and Embase databases were searched from inception to March 7, 2022. Immunogenicity involving serum antibodies against different SAS-CoV-2 fragments, neutralizing antibody, or spike-specific T cells response were compared. Any, local and systemic reactions were pooled by meta-analysis for comparison. Results Of 14,571 records identified, 13 studies (3024 participants) were included for analysis. Compared with homologous BNT/BNT vaccination, heterologous ChAd/BNT schedule probably induced noninferior anti-spike protein while higher neutralizing antibody and better T cells response. Heterologous ChAd/BNT (mRNA-1273) immunisation induced superior anti-spike protein and higher neutralizing antibody and better T cells response compared with homologous ChAd/ChAd vaccination. Heterologous ChAd/BNT (mRNA-1273) had similar risk of any reaction (RR = 1.30, 95% CI: 0.86−1.96) while higher risk of local reactions (RR = 1.65, 95% CI: 1.27−2.15) and systemic reactions (RR = 1.49, 95% CI: 1.17−1.90) compared with homologous ChAd/ChAd vaccination. There was a higher risk of local reactions (RR = 1.16, 95% CI: 1.03−1.31) in heterologous ChAd/BNT (mRNA-1273) vaccination compare with homologous BNT/BNT but a similar risk of any reaction (RR = 1.03, 95% CI: 0.79−1.34) and systemic reactions (RR = 0.89, 95% CI: 0.60−1.30). Conclusions Heterologous ChAd/BNT schedule induced at least comparable immunogenicity compared with homologous BNT/BNT and better immunogenicity compared with homologous ChAd/ChAd vaccination. The synthetical evidence supported the general application of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines. Graphical Abstract
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2049-9957
Relation: https://doaj.org/toc/2049-9957
DOI: 10.1186/s40249-022-00977-x
URL الوصول: https://doaj.org/article/8107969da414439db0903fe63cc44707
رقم الأكسشن: edsdoj.8107969da414439db0903fe63cc44707
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20499957
DOI:10.1186/s40249-022-00977-x